chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, Tinnitus
Clinical narrative: "I" had a significant increase in tinnitus after the first vaccine dose primarily in what seems like "my" right ear.; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW6208) via an unspecified route of administration in the arm left on 21Mar2021 at 12:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The medical history included osteoporosis, minor tinnitus and allergies to penicillin and sulphates. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included multi vitamin (unspecified), calcium/vitamin d nos (MANUFACTURER UNKNOWN) and fish oil (MANUFACTURER UNKNOWN); all for unknown indications from unknown dates and unknown if ongoing. On 22Mar2021 at 21:00, after the first vaccine dose, the patient had significant increase in tinnitus primarily in what seemed like the right ear. The patient had slight tinnitus prior to vaccine, but had experienced a significant increase that was impacted the patient's ability to sleep. On 06Apr2021, the patient underwent RT-PCR test via nasal swab and the result was negative. The adverse events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the reported event. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the event significant increase in tinnitus was not resolved at the time of this report. The patient also received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the arm right on 11Apr2021 at 10:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Ear discomfort, Pain, Rhinorrhoea
Clinical narrative: Several body aches; Ears plugged; Runny nose; Loss of taste; Loss of smell; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 27Apr2021 at 08:30 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, anxiety, depression and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included piroxicam (PAXIL), losartan (MANUFACTURER UNKNOWN), vitamin d nos (VITAMIN D) and mirabegron (MIRANIX); all for an unknown indication from an unknown date and an unknown if ongoing. The patient previously took fluticasone propionate (FLONASE) for an unknown indication on an unknown date and experienced drug allergy. On 30Apr2021, the patient experienced several body aches, ears plugged, runny nose, loss of taste and smell. At the time of the report the patient had not gained back taste or smell. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events several body aches, ears plugged, runny nose, loss of taste and loss of smell were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Bursitis
Clinical narrative: This is a spontaneous report from a contactable consumer (patient). A 57-year-old male patient received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# ER8737), at the age of 57, via an unspecified route of administration, in left arm, on Apr 2, 2021, at 12:45, single dose, for COVID-19 immunisation. Medical history included known allergies to sulfa drugs.  Prior to vaccination, patient was not diagnosed with COVID-19. The patient did not take any concomitant medications. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. On Apr 16, 2021, patient experienced bursitis in the right elbow. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, patient has not tested for COVID-19. No therapeutic measures taken as a result of the events. The outcome of bursitis in the right elbow: unknown (at the time of this report). No follow-up attempts needed. No further information expected.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Erythema, Livedo reticularis, Rash
Clinical narrative: Rash develops when in direct sunlight on exposed skin; The skin appears red; The skin appears mottled; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0164) via an unspecified route of administration in the right arm on 07May2021 at 08:30 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high and covid-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not have known allergies. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included fluticasone propionate (FLONASE), fexofenadine hydrochloride (ALLEGRA) and valsartan (MANUFACTURER UNKNOWN) all for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0164) via an unspecified route of administration in the left arm on 16Apr2021 at 12:00 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. On 07May2021 at 12:00, the patient experienced rash when in direct sunlight on exposed skin, which did not itch and there were no bumps or lumps. It was reported that the skin appeared red and mottled and in one location the rash resembled a sunburn but was not hot to the touch and did not hurt. It was reported that as soon as the patient went inside or in deep shade the rash disappeared within 15 minutes to a maximum of 30 minutes. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events rash when in direct sunlight on exposed skin, the skin appeared red and mottled were recovered on 07May2021.   No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Dizziness, Palpitations
Clinical narrative: Extreme dizziness; Heart racing; Diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 04May2021 at 12:15 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history included kidney disease, asthma, high blood pressure, thoracic outlet syndrome and carpal tunnel.  Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the vaccination. The patient did not receive any medications within two weeks of vaccination. The patient previously received influenza vaccine (MANUFACTURER UNKNOWN) and experienced allergy to flu vaccine; ethinylestradiol; etonogestrel (NUVARING) and experienced drug allergy. On 04May2021 at 13:00, the patient experienced extreme dizziness, heart racing and diarrhea. The dizziness had not stopped. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme dizziness, heart racing and diarrhea was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Computerised tomogram, Flank pain
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737, also reported as EW0170) via an unspecified route of administration in the arm left on 01Apr2021 at 16:00 as a single dose for COVID-19 immunisation. Medical history included high blood pressure and anxiety. No known allergies were reported. Concomitant medications included venlafaxine hydrochloride (EFFEXOR) and metoprolol (MANUFACTURER UNKNOWN); both since an unknown date for unknown indication and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 02Apr2021 at 02:00, the patient experienced flank pain on left side after first vaccine. Constant went to emergency room(ER) and received CAT scan and result was no finding for upper left quadrant. The patient also reported that pain was still present after 6 weeks. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of flank pain on left side after first vaccine and included CAT scan on an unknown date. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event flank pain on left side after first vaccine was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Peripheral swelling, Rash, SARS-CoV-2 test, Urticaria
Clinical narrative: Full body rash and hives; Full body rash and hives; Swelling in fingers from the hives; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0175) via an unspecified route of administration in the right arm on 04May2021 at 12:15 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history included allergic to cats and dust mites. It was reported that the patient was not that aware of known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 13Apr2021 at 12:15 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. On 06May2021, the patient underwent Nasal swab and the result was negative. On 07May2021 at 06:00, the patient experienced full body rash and hives and swelling in fingers from the hives. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events and which included treatment with diphenhydramine hydrochloride (BENADRYL). Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events full body rash and hives and swelling in fingers from the hives was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Muscle discomfort, Neck pain, Pain in extremity
Clinical narrative: I have had a dull ache in this arm since I got the injection; Over the last few days a knot has developed in the muscle. (At least-- that's what it feels like.) It is causing soreness in my neck and shoulder as well.; Over the last few days a knot has developed in the muscle. (At least-- that's what it feels like.) It is causing soreness in my neck and shoulder as well.; Over the last few days a knot has developed in the muscle. (At least-- that's what it feels like.) It is causing soreness in my neck and shoulder as well.; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 30Mar2021 at 16:00 at the age of 48-years-old as a single dose for COVID-19 immunisation. Medical history included asthma, arthritis, blood pressure high (HBP), and known allergies to several food and environmental allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included SINGULAIR, ZOLOFT, PROCARDIA, METFORMIN, and TIZANIDIN, all for unknown indication from unknown date unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received VIOXX for an unknown indication on an unknown date and experienced drug allergy. On 30Mar2021 at 21:00, the patient experienced a dull ache in this arm since she got the injection. On an unknown date in 2021, over the last few days, the patient experienced a knot had developed in the muscle (at least-- that's what it feels like) and it was causing soreness in her neck and shoulder as well. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with antiinflammatories, ice, and rest. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events a dull ache in this arm since she got the injection, a knot had developed in the muscle (at least-- that's what it feels like) and it was causing soreness in her neck and shoulder as well was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Chills, Discomfort, Dizziness
Clinical narrative: Headache by next morning; Low grade fever (max 100.4F); Joint aches; Muscle aches; Strong deltoid pain at injection site; Body heaviness; Fatigue; Chills in the night; Inability to sleep the first night; slight wooziness in the first 1-2 hours after injection; Pain in old injuries a couple days after; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 03May2021 at 09:15 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included vitamin d nos (MANUFACTURER UNKNOWN) taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the right arm on 11Apr2021 at 09:15 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. On 03May2021, 1-2 hours after the injection, the patient experienced slight wooziness. On 03May2021 at 21:30, the patient experienced low grade fever (maximum 100.4F), joint/muscle aches, strong deltoid pain at injection site, body heaviness, fatigue, chills in the night and inability to sleep the first night. On 03May2021, the patient underwent body temperature and the result was low grade fever (maximum 100.4 Fahrenheit). On an unknown date in May2021, couple of days after, patient experienced pain in old injuries. On 04May2021, by next morning, the patient experienced headache. The patient also reported that symptoms are generally began 12-15 hours after injection and primary symptoms were lasted for 24 hours from time of onset. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events slight wooziness, low grade fever (maximum 100.4F), joint/muscle aches, strong deltoid pain at injection site, body heaviness, fatigue, chills in the night, inability to sleep the first night, pain in old injuries and headache was recovered on an unspecified date in May2021.  No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Insomnia, Myalgia, Pain
Clinical narrative: Headache by next morning; Low grade fever (max 100.4F); Joint aches; Muscle aches; Strong deltoid pain at injection site; Body heaviness; Fatigue; Chills in the night; Inability to sleep the first night; slight wooziness in the first 1-2 hours after injection; Pain in old injuries a couple days after; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 03May2021 at 09:15 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included vitamin d nos (MANUFACTURER UNKNOWN) taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the right arm on 11Apr2021 at 09:15 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. On 03May2021, 1-2 hours after the injection, the patient experienced slight wooziness. On 03May2021 at 21:30, the patient experienced low grade fever (maximum 100.4F), joint/muscle aches, strong deltoid pain at injection site, body heaviness, fatigue, chills in the night and inability to sleep the first night. On 03May2021, the patient underwent body temperature and the result was low grade fever (maximum 100.4 Fahrenheit). On an unknown date in May2021, couple of days after, patient experienced pain in old injuries. On 04May2021, by next morning, the patient experienced headache. The patient also reported that symptoms are generally began 12-15 hours after injection and primary symptoms were lasted for 24 hours from time of onset. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events slight wooziness, low grade fever (maximum 100.4F), joint/muscle aches, strong deltoid pain at injection site, body heaviness, fatigue, chills in the night, inability to sleep the first night, pain in old injuries and headache was recovered on an unspecified date in May2021.  No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vaccination site pain
Clinical narrative: Headache by next morning; Low grade fever (max 100.4F); Joint aches; Muscle aches; Strong deltoid pain at injection site; Body heaviness; Fatigue; Chills in the night; Inability to sleep the first night; slight wooziness in the first 1-2 hours after injection; Pain in old injuries a couple days after; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 03May2021 at 09:15 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included vitamin d nos (MANUFACTURER UNKNOWN) taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the right arm on 11Apr2021 at 09:15 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. On 03May2021, 1-2 hours after the injection, the patient experienced slight wooziness. On 03May2021 at 21:30, the patient experienced low grade fever (maximum 100.4F), joint/muscle aches, strong deltoid pain at injection site, body heaviness, fatigue, chills in the night and inability to sleep the first night. On 03May2021, the patient underwent body temperature and the result was low grade fever (maximum 100.4 Fahrenheit). On an unknown date in May2021, couple of days after, patient experienced pain in old injuries. On 04May2021, by next morning, the patient experienced headache. The patient also reported that symptoms are generally began 12-15 hours after injection and primary symptoms were lasted for 24 hours from time of onset. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events slight wooziness, low grade fever (maximum 100.4F), joint/muscle aches, strong deltoid pain at injection site, body heaviness, fatigue, chills in the night, inability to sleep the first night, pain in old injuries and headache was recovered on an unspecified date in May2021.  No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspepsia, Fatigue, Nausea, Vertigo
Clinical narrative: Fatigue; Nausea; Vertigo; Indigestion; Severe heartburn; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 16Apr2021 at 12:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included celiac disease since an unknown date and known allergy to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Mar2021 at 12:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. On 17Apr2021 at 09:00, the patient experienced fatigue, nausea, vertigo, indigestion and severe heart burn. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the events nausea, indigestion and severe heart burn which included treatment with unspecified medication (Medication for Gi issues). The clinical outcome of the events fatigue, nausea, vertigo, indigestion and severe heart burn was not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Lip pain, Lip swelling
Clinical narrative: my lips were swollen about 4 times the normal size, extremely hard like a rock, and painful to the touch. Hard to close my mouth,; my lips were swollen about 4 times the normal size, extremely hard like a rock, and painful to the touch. Hard to close my mouth,; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 20Apr2021 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included amfetamine aspartate/amfetamine sulfate/dexamfetamine saccharate/dexamfetamine sulfate (ADDERALL) for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 21Apr2021, second night after the vaccination, the patient experienced her lips were swollen about 4 times the normal size, extremely hard like a rock, and painful to touch and hard to close her mouth, but she took Benadryl right away and continued the following day as well and the swelling subsided. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with diphenhydramine hydrochloride (BENADRYL). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events lips were swollen about 4 times the normal size, extremely hard like a rock, and painful to touch and hard to close mouth was resolved on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Rash papular
Clinical narrative: woke up with dozens upon dozens of red bumps all over my back; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration on an unknown date in 2021 as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. On 05May2021 the patient reported that after a weeks of her first shot and the other day she woke up with dozens upon dozens of red bumps all over her back, she told that it was not normal acne, and not a diet change as well, which was highly unusual for her and she felt horribly self conscious and uncomfortable, since this was her reaction after the first dose, she was not sure what the "crueler dose #2 would do" to her body. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19.The clinical outcome of the event woke up with dozens upon dozens of red bumps all over back was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Heart rate, Heart rate decreased, Hypoaesthesia, Pain
Clinical narrative: Rash; Shooting pain in neck; Room is spinning looks like I amriding a merry go round; Dizzy; Light headed; Low heart rate followed by spurts of quick, off rhythm beats; Numbness in arms and hands; This is a spontaneous report from a contactable healthcare professional, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM8731) via an unspecified route of administration in the left arm on 06May2021 at 11:15 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included celiac disease and allergic to penicillin allergy, gluten, chocolate and tree nuts. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications were not reported. On 07May2021 at 16:30, the patient experienced rash, shooting pain in neck, room was spinning- looks like the patient was riding a merry go round, dizzy, light headed, low heart rate followed by spurts of quick, off rhythm beats and numbness in arms and hands. On 07May2021, the patient underwent heart rate rest and the result was decreased heart rate. The events did not result in doctor or other healthcare professional office, clinic visit, emergency room, department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events rash, shooting pain in neck, room was spinning- looks like the patient was riding a merry go round, dizzy, light headed, low heart rate followed by spurts of quick, off rhythm beats and numbness in arms and hands was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Vertigo
Clinical narrative: Rash; Shooting pain in neck; Room is spinning looks like I amriding a merry go round; Dizzy; Light headed; Low heart rate followed by spurts of quick, off rhythm beats; Numbness in arms and hands; This is a spontaneous report from a contactable healthcare professional, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM8731) via an unspecified route of administration in the left arm on 06May2021 at 11:15 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included celiac disease and allergic to penicillin allergy, gluten, chocolate and tree nuts. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications were not reported. On 07May2021 at 16:30, the patient experienced rash, shooting pain in neck, room was spinning- looks like the patient was riding a merry go round, dizzy, light headed, low heart rate followed by spurts of quick, off rhythm beats and numbness in arms and hands. On 07May2021, the patient underwent heart rate rest and the result was decreased heart rate. The events did not result in doctor or other healthcare professional office, clinic visit, emergency room, department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events rash, shooting pain in neck, room was spinning- looks like the patient was riding a merry go round, dizzy, light headed, low heart rate followed by spurts of quick, off rhythm beats and numbness in arms and hands was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Rash; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 28Apr2021 at 15:30 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included LAMICTAL from an unknown date for an unknown indication and unknown if ongoing. The patient previously received CODEINE for an unknown indication on an unknown date and experienced drug allergy. On 30Apr2021 at 13:00, the patient experienced rash. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event rash was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 16.0
Sex: F
Vaccine: COVID19
Symptoms: Hyperhidrosis, Nasopharyngitis, Nausea, Odynophagia, Oral pain
Clinical narrative: Pain with swallowing; Stinging pain/ soreness in top right soft palate of mouth; Nausea; Extreme cold for minutes after the nausea; Excess sweating for minutes after the nausea; This is a spontaneous report from a contactable consumer, the patient. A 16-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02May2021 (at the age of 16-years-old) as a single dose for COVID-19 immunisation. Medical history included mild allergy to shrimp and coconut oil. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medication within two weeks of vaccination. On 02May2021, the patient experienced nausea for first few minutes of vaccine and extreme cold and excess sweating for minutes after the nausea. On 05May2021, the patient currently experiencing stinging pain or soreness in top right soft palate of mouth. Pain with swallowing that has persisted for 3 days. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events nausea, extreme cold, excess sweating and stinging pain or soreness in top right soft palate of mouth were unknown at the time of this report. The clinical outcome of the event pain with swallowing was resolved on an unknown date in May2021, after the duration of 3 days.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy
Clinical narrative: Swollen lymph node in left armpit area that is very painful. This is the same side my moderna booster shot was given.
Age: 31.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Cough, Headache, Myalgia, Nausea
Clinical narrative: Chills; Nausea; Headache; Muscle soreness; Cough; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 06May2021 at 09:30 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic migraines. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 07May2021 at 02:00, the patient experienced chills, nausea, headache, muscle soreness and cough. The patient had none prior to vaccine and all had cropped up last night (07May2021). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, nausea, headache, muscle soreness and cough was resolving at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Glossodynia, Swollen tongue
Clinical narrative: By the evening of Day 2, swelling and soreness on tongue developed.; By the evening of Day 2, swelling and soreness on tongue developed.; In addition an odd taste is left in mouth.; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration in the arm left on 02May2021 at 12:15 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The medical history was reported as none. The patient's known allergies were reported as none. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included atomoxetine (MANUFACTURER UNKNOWN), dexmethylphenidate (MANUFACTURER UNKNOWN) and levonorgestrel (NORTREL), all for unknown indications from unknown dates and unknown if ongoing.  On 03May2021 at 16:00, by the evening of day 2,the patient developed swelling and soreness on tongue, in addition to that an odd taste was left in mouth. The patient reported that she was on day 3 and the swelling of tongue had caused her the need to took BENADRYL in addition to acetaminophen. She stated that her husband was having no other side effects in comparison to hers. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events swelling and soreness on tongue and included treatment with diphenhydramine hydrochloride (BENADRYL) and acetaminophen (MANUFACTURERE UNKNOWN). The patient did not receive any treatment for the event odd taste in mouth. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swelling and soreness on tongue and an odd taste was left in mouth were resolving at the time of this report. No follow-up attempts are possible. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Pain in extremity, SARS-CoV-2 test
Clinical narrative: Entire Right arm (not the injection site arm) has been painful including the joint.; Entire Right arm (not the injection site arm) has been painful including the joint.; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 05Apr2021 at 17:15 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. The medical history included type II diabetic. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included biotin (MANUFACTURER UNKNOWN) and probiotics (unspecified), all for unknown indications from unknown dates and unknown if ongoing. On 09Mar2020, the patient underwent Nasal Swab, SARS-CoV2 test and the result was negative. On 24Apr2021 at 14:15, the patient's entire right arm (not the injection site arm) had been painful including the joint and it seemed like the muscles and bone were affected. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events entire right arm (not the injection site arm) had been painful including the joint was resolving at the time of this report. The patient also received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 26Apr2021 at 15:45 (at the age of 37-years-old) as a single dose for COVID-19 immunisation.    No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Chills, Fatigue, Heart rate
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the right arm on 03May2021 at 12:45 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included hepatitis A in 1978, heart murmur. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID -19. Concomitant medications included colecalciferol/ calcium carbonate/ magnesium oxide (CAL MAG D) for unknown indication from an unspecified date, unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the right arm on 12Apr2021 at 12:45 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. On 03May2021 at 14:00, the patient experienced fever up to 100.3 (unspecified units) for 24 hours, fever lingered at 99.5 (unspecified unit) for 36 hours. Chills, nausea, joint pain in every joint. Exhaustion and elevated resting heart rate (normally 66) at the time of reporting 88 continued for 4 days. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/ department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the events fever, chills, nausea, joint pain in every joint, exhaustion and elevated resting heart rate was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Heart rate increased, Nausea, Pyrexia
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the right arm on 03May2021 at 12:45 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included hepatitis A in 1978, heart murmur. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID -19. Concomitant medications included colecalciferol/ calcium carbonate/ magnesium oxide (CAL MAG D) for unknown indication from an unspecified date, unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the right arm on 12Apr2021 at 12:45 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. On 03May2021 at 14:00, the patient experienced fever up to 100.3 (unspecified units) for 24 hours, fever lingered at 99.5 (unspecified unit) for 36 hours. Chills, nausea, joint pain in every joint. Exhaustion and elevated resting heart rate (normally 66) at the time of reporting 88 continued for 4 days. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/ department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the events fever, chills, nausea, joint pain in every joint, exhaustion and elevated resting heart rate was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Euphoric mood, Illusion
Clinical narrative: Feeling almost high; Visually things look super real and cant stop focusing on tiny things like insects or lint and it feels like overwhelming visual detail; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) in the arm left on 06May2021 at 14:30 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included MGUS (monoclonal gammopathy of undetermined significance) and hemicrania had known allergies to sulfa drugs (sulfonamide allergy). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included spironolactone (MANUFACTURER UNKNOWN) and indometacin (INDOMETHACIN), both were taken for unspecified indication on an unknown date and unknown if ongoing. The patient previously received codeine (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient previously received the first dose first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) in the arm left on 15Apr2021 at 14:30 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. On 07May2021, the patient experienced feeling almost high, visually things look super real and can't stop focusing on tiny things like insects or lint and it feels like overwhelming visual detail. It was reported that it happened after the first dose too and went away in a few hours. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events feeling almost high, visually things look super real and can't stop focusing on tiny things like insects or lint and it feels like overwhelming visual detail were not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.